Phase III Trial Tests Blood-Based MRD Monitoring to Spare Breast Cancer Patients CDK4/6 Inhibitor Toxicity
The new global phase III AFT-70 NAVIGATE trial will test whether ultrasensitive Signatera MRD blood monitoring can safely guide CDK4/6 ...
Tag: SERD
Oral Giredestrant Combination Nearly Doubles Survival Without Progression in Metastatic Breast Cancer
The phase 3 evERA study found that an all-oral combination of the next-generation estrogen receptor degrader giredestrant and everolimus significantly ...
ESR1 Testing Stays Rare in Metastatic Breast Cancer Even as Mutations Emerge
A real-world study of over 8,500 US patients with ER-positive/HER2-negative metastatic breast cancer found that ESR1 mutation testing remains rare ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!